JCR Pharmaceuticals Co Ltd 2024 IR
The report highlights JCR Pharmaceuticals' commitment to developing treatments for rare and ultra-rare diseases, particularly through its proprietary J-Brain Cargo technology which crosses the blood-brain barrier. It outlines the company's global expansion efforts, sustainability governance, and progress on material issues during the fiscal year ended March 31, 2024. Key achievements include advancing clinical trials for lysosomal storage disorders and establishing strategic partnerships to address unmet medical needs.
Company: JCR Pharmaceuticals Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 12
JCR Pharmaceuticals Co Ltd
Corporate Report
The report highlights JCR Pharmaceuticals' commitment to developing treatments for rare and ultra-rare diseases, particularly through its proprietary J-Brain Cargo technology which crosses the blood-brain barrier. It outlines the company's global expansion efforts, sustainability governance, and progress on material issues during the fiscal year ended March 31, 2024. Key achievements include advancing clinical trials for lysosomal storage disorders and establishing strategic partnerships to address unmet medical needs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees